Some lung cancer patients may experience durable disease control even after discontinuing immunotherapy

by

A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due to immune-related adverse events (irAEs) continued to experience long-term disease control, according to findings published in Clinical Cancer Research.

Leave A Comment

Your email address will not be published. Required fields are marked *